Approved for To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva. Side effects, costs, interactions, manufacturer, and generic alternatives sourced from FDA labels, openFDA FAERS, and CMS NADAC pricing.
Loading full data from Know Your Drugs Institute…